MAGE-12 (127-141)

MAGE-12 (127-141) is a synthetic peptide fragment derived from the melanoma-associated antigen gene family, specifically corresponding to amino acid residues 127 to 141 of the MAGE-12 protein. As a member of the MAGE family, this peptide is of significant interest in immunological and cancer research due to its association with tumor-specific antigens and restricted expression patterns in normal tissues. The unique sequence of MAGE-12 (127-141) enables detailed investigation of antigenic epitopes, T-cell recognition, and peptide-MHC binding dynamics. Its use as a research tool supports the elucidation of molecular mechanisms underlying antigen processing, immune surveillance, and tumor immunogenicity.

Epitope Mapping: MAGE-12 (127-141) serves as a defined sequence for mapping immunodominant epitopes within the MAGE-12 protein. Researchers utilize this peptide to identify and characterize the exact regions recognized by cytotoxic T lymphocytes (CTLs) and helper T cells. By employing this fragment in epitope mapping assays, scientists can dissect the specificity of immune responses, facilitating the identification of potential immunogenic hotspots relevant to tumor immunology and antigen presentation studies.

T-Cell Activation Studies: The peptide is frequently used in functional assays to evaluate T-cell activation and specificity. By presenting MAGE-12 (127-141) in the context of major histocompatibility complex (MHC) molecules, investigators can assess the activation threshold, cytokine production, and cytolytic activity of antigen-specific T cells. These studies are pivotal for understanding the immune repertoire against tumor-associated antigens and for designing experimental systems to probe T-cell receptor (TCR) engagement and downstream signaling pathways.

Peptide-MHC Binding Assays: As a well-defined antigenic fragment, this peptide is instrumental in quantitative binding studies with various MHC class I and II molecules. Researchers employ it to determine peptide affinity, stability, and the structural basis of MHC-peptide interactions. Such assays provide critical insights into the rules governing antigen presentation, inform computational modeling of peptide binding, and support the rational design of peptide-based reagents for immunological applications.

Immunoassay Development: MAGE-12 (127-141) is incorporated into the development and optimization of immunoassays, such as ELISPOT, ELISA, and flow cytometry-based detection formats. By serving as a positive control or as a defined antigenic stimulus, the peptide enables precise quantification of antigen-specific immune responses. This application is especially valuable in the context of monitoring immune reactivity in experimental tumor models or in the validation of novel immunological reagents.

Antigen Processing Research: The synthetic nature of this peptide allows researchers to investigate the intracellular pathways involved in antigen processing and presentation. By introducing the peptide into cellular systems, scientists can trace its processing, transport, and eventual display on MHC molecules at the cell surface. These studies contribute to a deeper understanding of the molecular machinery responsible for generating peptide-MHC complexes and the factors influencing antigenicity and immune recognition in the context of tumor-associated antigens.

1. Novel Peptide-Based PD1 Immunomodulators Demonstrate Efficacy in Infectious Disease Vaccines and Therapeutics

2. Quantitative Analysis of Ligands Effects on Bioefficacy of Nanoemulsion encapsulating Depigmenting Active

3. The effect of B-type allatostatin neuropeptides on crosstalk between the insect immune response and cold tolerance

4. Oleic acid and glucose regulate glucagon-like peptide 1 receptor expression in a rat pancreatic ductal cell line

5. Immune-awakening Saccharomyces-inspired nanocarrier for oral target delivery to lymph and tumors